Table 1.

Clinical and laboratory characteristics of the study populations

Variables	KD mean (range)	Pneumonia mean (range)	HFMD mean (range)	URI mean (range)	P value
n	64	74	31	49
Gender					0.439
Male	42	45	14	29
Female	22	29	17	20
Age (years)	2.49 ± 2.26 (0.5–10)	3.61 ± 2.81 (0.17–12)	2.59 ± 3.53 (0.67–18)	3.56 ± 3.43 (0.08–14)	0.019a
BT (°C)	38.58 ± 0.71 (37–40)	38.41 ± 1.01 (37–40)	38.04 ± 0.98 (37–39.8)	38.37 ± 1.15 (36–41.1)	0.453
WBC (103/μl)	13.16 ± 8.09 (3.10–59.0)	10.45 ± 6.10 (2.2–33.03)	10.15 ± 4.34 (3.3–21.4)	9.28 ± 3.97 (2.75–20.86)	0.195
RBC (103/μl)	3.98 ± 0.51 (2.81–5.74)	4.2 ± 0.54 (3–5.91)	4.3 ± 0.42 (3.78–5.36)	4.4 ± 0.46 (3.19–6.03)	0.319
Hb (g/dl)	10.65 ± 1.34 (7–14.6)	11.43 ± 1.57 (9.7–19.3)	11.37 ± 1.03 (9.28–13.6)	11.57 ± 1.28 (8.3–14.3)	0.050
PLT (103/μl)	404.64 ± 161.68 (182–827)	272.76 ± 115.07 (2.58–510)	274 ± 105.9 (101–531)	282.06 ± 107.72 (14–545)	0.004a
CRP (μg/ml)	78.05 ± 67.45 (3.19–305)	32 ± 58.05 (1.24–282)	18.54 ± 18.96 (1.52–68.6)	16.13 ± 40.33 (1.24–237)	0.070
Hp (mg/dl)	325.73 ± 107.63 (114–577)	175.75 ± 112.46 (5.83–520)	218.54 ± 79.82 (56.5–370)	142.47 ± 78.57 (5.83–321)	<0.001a
apoA-I (mg/dl)	108.99 ± 28.49 (55.1–171)	110.25 ± 37.32 (25–193)	102.59 ± 36.25 (25–263)	114.34 ± 28.07 (53.4–211)	0.008a
apoB (mg/dl)	97.93 ± 32.62 (44–211)	74.05 ± 24.85 (16.5–133)	96.16 ± 28.73 (35–165)	67.98 ± 20.53 (35–116)	<0.001a
HAR	4.74 ± 2.73 (0.98–13.54)	2.03 ± 1.88 (0.03–9.67)	2.24 ± 1.19 (0.55–5.39)	1.4 ± 0.98 (0.04–4.69)	<0.001a

Data are presented as mean ± standard deviation. The P value compares the KD group with the other groups using multiple logistic regression analysis

^aStatistically significant

KD Kawasaki disease, HFMD hand, foot, and mouth disease, URI upper respiratory tract infection, BT body temperature, WBC white blood cell count, RBC red blood cell count, Hb hemoglobin, PLT platelets, CRP C-reactive protein, Hp haptoglobin, apoA-I apolipoprotein A-I, apoB apolipoprotein B, HAR haptoglobin/apolipoprotein A-I ratio